Compare · BIO vs EYPT
BIO vs EYPT
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and EyePoint Inc. (EYPT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and EYPT operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- BIO is the larger of the two at $9.65B, about 363.0x EYPT ($26.6M).
- EYPT has been more active in the news (9 items in the past 4 weeks vs 2 for BIO).
- EYPT has more recent analyst coverage (20 ratings vs 12 for BIO).
- Company
- Bio-Rad Laboratories Inc.
- EyePoint Inc.
- Price
- -
- -
- Market cap
- $9.65B
- $26.6M
- 1M return
- -
- -44.89%
- 1Y return
- -
- -98.28%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- News (4w)
- 2
- 9
- Recent ratings
- 12
- 20
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
EyePoint Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Latest BIO
- Bio-Rad Reports Third-Quarter 2026 Financial Results
- Bio-Rad to Participate in Fireside Chat During UBS Global Healthcare Conference
- Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026
- Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
- Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference
- IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx
- Bio-Rad Reports Second-Quarter 2026 Financial Results
- Bio-Rad to Report Second-Quarter 2026 Financial Results on Tuesday, August 4, 2026
- RBC Capital Mkts resumed coverage on Bio-Rad Labs with a new price target
- Bio-Rad to Participate in Upcoming Investor Conferences
Latest EYPT
- EyePoint Inc. filed SEC Form 8-K: Other Events
- Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.
- SEC Form 10-Q filed by EyePoint Inc.
- EyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- EyePoint Reports Third Quarter 2026 Financial Results and Provides Recent Corporate Developments
- EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
- EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
- Amendment: SEC Form SCHEDULE 13G/A filed by EyePoint Inc.
- SEC Form SCHEDULE 13G filed by EyePoint Inc.
- EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)